Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The current status and emerging trends in the application of precision nutrition for the comprehensive, lifecycle-based management of chronic liver diseases.

Frontiers in nutrition·2026
Same author

STNAGNN: Data-driven Spatio-temporal Brain Connectivity beyond FC.

Proceedings of machine learning research·2026
Same author

<i>MFAP2</i> Promotes Glioblastoma Malignant Phenotypes via Autophagy-Dependent Activation of Wnt/β-Catenin Signaling.

Biomedicines·2026
Same author

HYPERBOLIC MODEL AGGREGATION FOR FEDERATED LEARNING IN FMRI.

Proceedings. IEEE International Symposium on Biomedical Imaging·2026
Same author

Clinical discovery of anti-CYP2E1 autoantibodies and preclinical efficacy of a CYP2E1 inhibitor in rheumatoid arthritis.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Centromere protein I promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR-CDK2 cascade.

Cancer biology & therapy·2026
Same journal

Corrigendum to: Nanocochleates in Clinical Trials: A Review of Current Status, Challenges, and Future Directions.

Current drug metabolism·2026
Same journal

Shenfu Decoction Extends Survival Time of Seawater-Induced Hypothermia in Rats: The Role of Metabolomics and Gut Microbiota.

Current drug metabolism·2026
Same journal

Nucleic Acid Nanomaterials Targeting Autophagy in Bone Regeneration.

Current drug metabolism·2026
Same journal

Nicotinamide N-Methyltransferase (NNMT): A Central Regulator in Hepatocellular Carcinoma Metabolism and Therapeutic Targeting - A Systematic Review.

Current drug metabolism·2026
Same journal

Unraveling the Gut Microbiota-Mediated Mechanism of Guogong Jiu for Rheumatoid Arthritis Treatment through Network Pharmacology and Metabolomics.

Current drug metabolism·2026
Same journal

Cytochrome P450-derived Polyunsaturated Fatty Acid Metabolites as Modulators of Tumoral Hypoxia-induced Angiogenesis: From Mechanism to Anticancer Therapeutic Perspectives.

Current drug metabolism·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Chlorzoxazone-based One-Sample Method for Estimating In Vivo CYP2E1 Activity in Mice.

Cunzhen Zhang1, Rui Yang1, Jun Ma1

  • 1Institute of Clinical Pharmacology, School of Basic Medical Sciences, Zhengzhou University; Zhengzhou, 450001, China.

Current Drug Metabolism
|May 8, 2026
PubMed
Summary
This summary is machine-generated.

A new method using chlorzoxazone (CZX) and its metabolite 6-hydroxy CZX (6-OH CZX) simplifies evaluating cytochrome P450 2E1 (CYP2E1) activity in vivo. The 15-minute metabolite ratio (MR) and CZX half-life (t₁/₂) are sensitive indicators of CYP2E1 function.

Keywords:
CYP2E1activitychlorzoxazonemetabolite ratiomicemicrosome

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

Related Experiment Videos

Last Updated: May 9, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies
07:59

Demystifying In Vivo Bioluminescence Imaging of a Chagas Disease Mouse Model for Drug Efficacy Studies

Published on: May 31, 2024

Area of Science:

  • Pharmacology
  • Biochemistry
  • Analytical Chemistry

Background:

  • Cytochrome P450 2E1 (CYP2E1) is vital for drug metabolism and disease processes.
  • Traditional methods for assessing in vivo CYP2E1 activity are complex and less sensitive.
  • Developing a simpler, more sensitive assay for CYP2E1 activity is crucial.

Purpose of the Study:

  • To develop and validate a sensitive HPLC-UV method for quantifying chlorzoxazone (CZX) and 6-hydroxy CZX (6-OH CZX) in mouse plasma.
  • To establish and validate four distinct mouse models representing varying levels of CYP2E1 activity.
  • To compare the sensitivity of pharmacokinetic parameters and the metabolite ratio (MR) for characterizing in vivo CYP2E1 activity.

Main Methods:

  • Developed and validated an HPLC-UV method for CZX and 6-OH CZX analysis.
  • Created four mouse models: high CYP2E1 activity (isoniazid), low activity (Q11 inhibitor, Cyp2e1 knockout, CCl₄).
  • Analyzed pharmacokinetic parameters (t₁/₂, AUC, CL) and the 6-OH CZX/CZX ratio (MR) at different time points.

Main Results:

  • The HPLC-UV method demonstrated excellent specificity, linearity, and precision.
  • Established mouse models confirmed distinct CYP2E1 activity levels via in vitro assays.
  • CZX half-life (t₁/₂) was more sensitive than AUC or CL for assessing CYP2E1 activity.
  • The 15-minute MR showed the strongest correlation with microsomal CYP2E1 activity (r=0.57) and CZX t₁/₂ (r=0.83).

Conclusions:

  • The 15-minute MR and CZX t₁/₂ provide a simplified and sensitive approach to evaluate in vivo CYP2E1 activity.
  • This method overcomes limitations of traditional pharmacokinetic analyses and existing MR methods.
  • The findings support the use of CZX as a probe for CYP2E1 activity, laying groundwork for future research in disease states.